Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Assets over the past 6 years, most recently at $1.2 billion for Q1 2026.

  • For Q1 2026, Assets fell 12.95% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, down 12.95%, while the annual FY2025 figure was $1.2 billion, 8.74% down from the prior year.
  • Assets for Q1 2026 was $1.2 billion at Indivior Pharmaceuticals, roughly flat from $1.2 billion in the prior quarter.
  • Over five years, Assets peaked at $1.9 billion in Q3 2023 and troughed at $1.2 billion in Q1 2026.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 define the central range for Assets.
  • Biggest five-year swings in Assets: decreased 0.62% in 2023 and later decreased 25.14% in 2024.
  • Year by year, Assets stood at $1.8 billion in 2022, then dropped by 0.62% to $1.8 billion in 2023, then fell by 25.14% to $1.3 billion in 2024, then fell by 8.74% to $1.2 billion in 2025, then fell by 0.33% to $1.2 billion in 2026.
  • Business Quant data shows Assets for INDV at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.4 billion in Q3 2025.